GlassScriptPhysician profile
Amanda M Malone
NPI 1033537428
$1,822.24
in general payments reported to CMS, 2019-2025
21 companies · $653 in 2025
The $653 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $263 · 2022: $111 · 2023: $196 · 2024: $598 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $397.43 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $338.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $332.28 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $129.44 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $92.57 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $73.42 | 2022 | |
| Exact Sciences Corporation | $64.51 | 2025 | The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $45.62 | 2021-2025 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.70 | 2024-2025 | Xifaxan |
| Amarin Pharma, INC. | $42.12 | 2021 | |
| Glaxosmithkline, LLC. | $37.36 | 2021-2025 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.08 | 2021-2025 | Jardiance |
| Amgen INC. | $32.80 | 2021-2025 | Krystexxa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.44 | 2025 | Caplyta |
| Dexcom, INC. | $25.11 | 2024 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $22.58 | 2024 | Vyepti |
| Merz North America, INC. | $21.48 | 2025 | |
| Axsome Therapeutics, INC. | $20.45 | 2025 | Auvelity |
| Dynavax Technologies Corporation | $15.51 | 2025 | Heplisav-B |
| Abbott Laboratories | $12.31 | 2021 | |
| Phathom Pharmaceuticals, INC. | $9.42 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.